0001493152-23-001628.txt : 20230117 0001493152-23-001628.hdr.sgml : 20230117 20230117163029 ACCESSION NUMBER: 0001493152-23-001628 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230112 FILED AS OF DATE: 20230117 DATE AS OF CHANGE: 20230117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nolet Chris CENTRAL INDEX KEY: 0001782814 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32404 FILM NUMBER: 23531864 MAIL ADDRESS: STREET 1: C/O REVANCE THERAPEUTICS, INC. STREET 2: 7555 GATEWAY BOULEVARD CITY: NEWARK STATE: CA ZIP: 94560 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: POLARITYTE, INC. CENTRAL INDEX KEY: 0001076682 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 061529524 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1960 S. 4250 WEST CITY: SALT LAKE CITY STATE: UT ZIP: 84104 BUSINESS PHONE: (385) 266-3151 MAIL ADDRESS: STREET 1: 1960 S. 4250 WEST CITY: SALT LAKE CITY STATE: UT ZIP: 84104 FORMER COMPANY: FORMER CONFORMED NAME: MAJESCO ENTERTAINMENT CO DATE OF NAME CHANGE: 20050427 FORMER COMPANY: FORMER CONFORMED NAME: MAJESCO HOLDINGS INC DATE OF NAME CHANGE: 20040416 FORMER COMPANY: FORMER CONFORMED NAME: CONNECTIVCORP DATE OF NAME CHANGE: 20010815 4 1 ownership.xml X0306 4 2023-01-12 1 0001076682 POLARITYTE, INC. PTE 0001782814 Nolet Chris C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD NEWARK CA 94560 1 0 0 0 Common Stock 2023-01-12 4 M 0 36497 0 D 14403 D Stock option (right to buy) 22.50 2023-01-12 4 M 0 3078 0.00 D 2030-04-06 Common Stock 9235 6157 D Pursuant to the issuer's non-executive director compensation plan the reporting person was issued 50,900 Restricted Stock Units vesting in equal installments quarterly in arrears, which were previously reported on Form 4 under Table I. As of the date of the reporting person's end of service as a director on January 12, 2023, 36,497 restricted stock units that had not vested as of that date were forfeited. The stock option was granted 04/06/2020, and reported under Table II of Form 4. The number of derivative securities and price have been adjusted to give effect to a 25-to-1 reverse stock split in May 2022. As of the date of the reporting person's end of service as a director on January 12, 2023, 3,078 stock options that had not vested as of that date were forfeited. The remaining 6,157 stock options were fully vested as of 04/06/2022, and are presently exercisable. /s/ Chris Nolet 2023-01-17